Browse the evidence

Effective weight loss, even when accompanied by gastrointestinal side effects, was associated with a greater willingness to continue Ozempic treatment.

Practitioners should emphasize the importance of weight loss effectiveness in encouraging patients to continue treatment despite side effects.

Semaglutide offers robust cardiovascular protection.

Clinicians can consider semaglutide for patients needing cardiovascular protection in obesity management.

BHB supplementation led to a reduction in LDL cholesterol in the BHB group.

BHB supplementation may improve lipid profiles in overweight and obese individuals.

GLP-1RAs appear to be safe and effective in patients with inflammatory bowel disease (IBD).

Healthcare providers can consider GLP-1RAs as a treatment option for IBD patients.

LLM responses had significantly higher scores than internet responses in the 'objectivity' and 'reproducibility' categories.

Practitioners may consider using LLMs for more objective and reproducible information on GLP1RA therapy.

Current therapeutic strategies for obesity include lifestyle interventions, pharmacologic treatments, and bariatric surgery.

Practitioners should consider a multi-faceted approach to obesity treatment.

Pharmacoeconomic analyses support the cost-effectiveness of combining behavioral, pharmacological, and surgical modalities for obesity treatment.

Integrating various treatment modalities can enhance cost-effectiveness in obesity management.

GLP-1RA users demonstrated significantly reduced pseudarthrosis rates at all time points: 6 months (8% vs. 12%; OR=0.702), 12 months (OR=0.730), and 24 months postoperatively (OR=0.788).

GLP-1RAs may be beneficial in reducing complications like pseudarthrosis in ACDF patients.

GLP-1RAs improve blood pressure regulation and lipid metabolism.

Incorporating GLP-1RAs may enhance management of blood pressure and lipid levels in diabetic patients.

Semaglutide significantly reduced the risk of major limb events (LEs) compared with control interventions, with an odds ratio of 0.70 (95% CI 0.60–0.82; P < 0.0001).

Semaglutide may be an effective treatment option for reducing the risk of PAD-related complications in patients with diabetes or obesity.

The protective effect of semaglutide on limb events was consistent across patient subgroups, including those with diabetes and obesity.

Semaglutide can be considered for diverse populations at risk of PAD.

Weight loss, regardless of the method used to achieve it, is inadvertently accompanied by lean body mass loss, to varying degrees.

Practitioners should be aware that weight loss methods may lead to loss of lean body mass.

The loss of lean body mass, including muscle, is a significant concern associated with weight loss treatments.

Practitioners should monitor muscle mass during weight loss interventions.

Treatment with tesamorelin led to marked reductions in waist circumference and improved lipid levels in a patient with nonobese visceral adiposity.

Tesamorelin may be an effective treatment for reducing visceral fat in specific HIV patients.

Glucagon-like peptide (GLP-1) receptor agonists may induce generalized weight loss but may not effectively target visceral abdominal fat.

GLP-1 receptor agonists may not be the best choice for targeting visceral fat in HIV patients.

Higher maximum semaglutide dose was associated with lower post-landmark risk of all-cause mortality (RR 0.42, p<0.001) and composite cardiovascular events (RR 0.51, p<0.001).

Practitioners should consider maximizing semaglutide dosage to enhance cardiovascular outcomes.

Semaglutide was associated with lower cardiovascular events than metformin, DPP-4 and SGLT2 inhibitors.

Semaglutide may be a preferable option for patients at risk of cardiovascular events compared to other medications.

1-year treatment persistence among individuals without diabetes initiating high-potency, weight loss-indicated GLP-1RA products increased from 33.2% in 2021 to 60.9% in 1H 2024.

Practitioners should note the significant improvement in treatment persistence, which may indicate better patient adherence and management strategies.

Semaglutide 1-year persistence rates increased from 33.2% in 2021 to 58.6% in 1H 2024.

The increase in semaglutide persistence suggests improved patient adherence, which may be beneficial for weight management strategies.

Tirzepatide 1-year persistence rates were 64.0% in 2023 and 64.8% in 1H 2024.

The high persistence rates for tirzepatide indicate its potential effectiveness and acceptance among patients for weight management.

Diabetes remission rates reach 78% for Roux-en-Y gastric bypass (RYGB) and 62% for sleeve gastrectomy (SG).

Bariatric surgery can be an effective treatment for diabetes in obese patients.

Bariatric surgery demonstrates durability of outcomes over decades, while pharmacotherapy often requires lifelong administration to maintain weight loss.

Bariatric surgery may provide more sustainable weight loss results compared to medications.

Both treatments did not negatively impact fat-free mass after 3 months.

Both treatments can be used without concern for loss of lean body mass.

Weight gain among persons with HIV on contemporary antiretroviral therapy can lead to overweight/obesity in the first 1 to 2 years, resulting in enhanced cardiometabolic risk.

Healthcare providers should monitor weight changes in persons with HIV on ART to mitigate cardiometabolic risks.